Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial-Reference-Cited by-同舟云学术

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

Published:2011-09-06 Issue:10 Volume:13 Page:947-954
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:

Author:

Lukashevich V.,Schweizer A.,Shao Q.,Groop P.-H.,Kothny W.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2011.01467.x/fullpdf

Reference21 articles.

1. The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study).;Thomas;Med J Aust,2006

2. Management of glycemia in patients with diabetes mellitus and CKD.;Lubowsky;Am J Kidney Dis,2007

3. Bristol-Myers Squibb Company. ® ® 2006

4. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.;Neumiller;Pharmacotherapy,2010

5. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population.;Schweizer;Diabetes Obes Metab,2010

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials;Diabetes, Metabolic Syndrome and Obesity;2024-03

2. Mechanistic Study on the Effect of Renal Impairment on the Pharmacokinetics of Vildagliptin and its Carboxylic Acid Metabolite;Pharmaceutical Research;2022-07-06

3. Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials;Therapeutic Advances in Drug Safety;2022-01

4. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials;BMJ;2021-01-13

5. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study;Diabetes Research and Clinical Practice;2020-04